ʻO kahi hoʻolālā o ka maʻi'āpilikia pilapula a me nā maʻi o nā mea hoʻohana (2016)

Authors Rash CJ, Weinstock J, Van Patten R

Carla J Rash,1 Jeremiah Weinstock,2 Ryan Van Patten2

1ʻO ke Kulanui Cardiology Calhoun - Ke ola olakino, UConn Health, Farmington, CT, USA; 2Keʻena ʻOihana, Psychology ma Saint Louis, St Louis, MO, USA

Hōʻuluʻulu:

I ka lima ʻelima o ka Ka Papa Hana Hoʻonaʻauao a me Heluhelu o nā Mino Lō (DSM-5), ka pelekikena pili i ka ʻekekema mai ka ʻāpana "Impulse Control Disorder" i ka ʻāpana "kahi pili a me ka mea e pili ana i ka addictive". Me kēia neʻe, ua lilo ka maʻi hoʻoleʻa i ka mea i hoʻohui ʻia e ka nonsubstance e pili ana i ka hoʻopulapula, e hoʻopiʻi ana i nā hiʻohiʻona like ma waena o ka pili ʻana i ka pili kīleʻa a me nā pilikia make. Hoʻopau kēia loiloi i kēia mau mea like, a me nā hoʻokaʻawale, ma waena o ka pāʻani pili a me nā pilikia pili. Kūkākūkā mau mea hoʻohālikelike, comorbidity, genetic a me ka physiological underpinnings, a me nā lāʻau lapaʻau e kūkākūkā ʻia.

Keywords: papa patele, ke kahua pilikia, ka pili pili i nā hanana, transdiagnostic kumu, addiction syndrome
 

Introduction

ʻO ke kīpē heʻaʻai (GD) he hoʻomau mauʻelepule he mau keehi i ka hopena ʻo ka mea pili i ka hopena a i ʻole ka pohō.1 No ka hoʻokō ʻana i nā koina, pono ka hōʻike o kēlā me kēia i ʻehā a i ʻole mau ʻoi aʻe mau hōʻailona i loko o kahi mahina 12. Hiki i ka GD ke hōʻike i ka manawa a i ʻole ka hoʻomau a ke helu ʻia nei e like me ka maʻalahi, hōʻoluʻolu a i ʻole ka paʻakikī ma muli o ka nui o nā hōʻailona i manaʻo ʻia. I ka lima ʻelima o ka Ka Papa Hana Hoʻonaʻauao a me Heluhelu o nā Mino Lō (DSM-5),1 Ua hoʻoili ʻia ka pāpaʻi pathological i ke GD a hoʻokaʻawale ʻia mai ka maʻi hakano ʻōpiopio i ka maʻi pili i kahi mea pili i kahi mea pili i kahi mea pili. He nui nā pilina ma waena o ka GD a me ka waiʻona a me nā maʻi hana lapaʻau (AUD / DUD) a loaʻa i nā kūmole hōʻike diagnostic, kiʻekiʻe kiʻekiʻe o ka comorbidity, ka hoʻopili like ʻana i nā genetika, nā hopena neurobiological like, a me nā hopena hana maʻamau. No nā kumu o kēia loiloi, pili ʻo AUD i ka hōʻino ʻona a hilinaʻi ʻole paha a e pili ana ka DUD i kekahi lāʻau lapaʻau a ʻole ʻona ʻole (nontobacco, nonalcohol) poʻomanaʻo a me ka mea e hilinaʻi ʻole ʻia ke ʻole ka hoʻomaopopo ʻia. I ka ʻike o ka haʻi ʻana o GD e like me ka mea i hoʻoili ʻole i ka hoʻohālikelike ʻana i ke ʻano o ka waiwai, e hāʻawi kēia pepa i kahi hōʻike o nā pilina hiki loa i waena o GD a me AUD / DUD mai etiology i ka hopena pili i ka mālama ʻana i nā wahi i hoʻopā ʻia e ka DSM-5 ka papa helu.

Nā hōʻailona Diagnostic

Aia nui ka mea nui ma kēlā ʻaoʻao DSM-5 Loaʻa iā GD a me AUD / DUD, i hāʻawi i ka mea mua DSM-III ua hoʻohālikelike ʻia nā paapaʻa ma ke ʻano o nā waiwai hilinaʻi o ka manawa o ka manawa.2 Eia nō naʻe, nā mana nui e noho i waena o nā hoʻonohonoho diagnostic ʻelua, a, no laila, ke DSM-5 Kāhea hana hana (SUD) Mea hana ʻoihana hana i hoʻopaʻa ʻia ma ka DSM-IV ʻO nā koina o ka GD me nā hoʻololi e hiki ai i ka hoʻopili ʻana i nā paʻuna SUD no GD.3 In 1 Pūnaewele, ke papa inoa nei mākou i nā mākaukau no GD a me AUD, e hōʻike ana i ka uhi ʻana a i ʻole nā ​​mea like e pili ana. ʻO nā mea me nā pale ikaika e pili pono ana i ka hoʻomanawanui, ka hoʻoneʻe ʻana, ka nalo o ka hoʻokele, a me nā hopena maikaʻi ʻole. No ka mahalo ʻana i ka hana hope, loaʻa i ka GD hoʻokahi mea e pili ana i ka hopena maikaʻi i ka pae kaiāulu, hoʻonaʻauao, a i ʻole nā ​​hana hana; no AUD, ʻehā mau mea e wehewehe i nā hopena maikaʻi ʻole i nā waihona ola ʻē aʻe (e like me, ke olakino noʻonoʻo noʻonoʻo, ke olakino kino). Ka hoʻokū ʻia ʻana nā huaʻōlelo ʻo AUD / DUD, e pili pū ana i kēia mau hopena hopena, e nānā ʻia no ka hoʻoneʻe hou ʻia a hiki hoʻi ke hoʻonui ʻia ma nā hoʻoponopono DSM e hiki mai ana,3 a laila e hoʻomaʻamaʻa ai i ka hoʻomau ʻia ʻoi aku ka nui o ka diagnostic ma waena o nā maʻi hoʻohui. Ka ʻōlelo nō paha, e hoʻonui ʻia ka hopena maikaʻi ʻole o GD no ka hoʻopili ʻana i nā waihona ʻē aʻe e like me ke olakino noʻonoʻo kino, akā hūnā pinepine ʻia i ka poʻe me ka maʻi.4,5 Ma keʻano kikoʻī, nā helu ʻelua o ka comorbidity6 a me ka hopena o ka moʻo ʻana i ka makehewa a me ka hoʻāʻo7,8 ua hōʻike ʻia e hoʻokiʻekiʻe ʻia i hoʻokahi kanaka me GD.

 
Pākuʻi 1 Hoʻohālikelike o DSM-5 ka pili ʻana i ka pāʻani ʻoki a me ka inu ʻawaʻene e hoʻohana pono ai i nā kūlike
'Apili: DSM-5, Diagnostic a me ka Heluhelu Helu no ka maʻi noʻonoʻo, he elima palapala.

ʻO kahi lua e pili ana i ka hana diagnostic pili ʻo ia ka hoʻoponopono i nā ʻano hana hoʻohui. Ma GD, ua kāhea kēia hale hana i ka nui o ka pāʻani me ka pili kālā, a he hopohopo ia hoʻi i ka hoʻihoʻi ʻana i nā ʻike pili mua, ʻo ka hoʻolālā ʻana i nā ʻike pili āpau, a me ka hoʻolālā ʻana i nā ala e loaʻa ai ke kālā kālā. No AUD, kahi mea hoʻohālikelike e pili ana i ka hoʻolimalimaʻana i ka manawa he nui, ka hoʻohana, a hoʻolaʻa hou paha mai ka hoʻohana ʻana i ka wai ʻona e kūlike me kekahi o nā hoʻolālā hoʻolālā i ʻike ʻia i loko o ka mea GD. Eia nō naʻe, ʻaʻole e hoʻopuka ka mea a ke kiko leo i ka māhele cognitive o ka preoccupation i hōʻike ʻia ma GD. Ka makemake makemake mai ke kīmai ʻona, ʻo nā mea hou i DSM-5, e hopu paha i kahi hapa o kēia kūkulu cognitive. ʻAʻole i hoʻohui ʻia kahi mea i makemake ʻia i nā koina GD, ʻaʻole ia i wehewehe pono i nā cravings. ʻOiai ke hōʻike nei nā hōʻike hōʻike i nā kuʻuna i waena o nā poʻe me GD9,10 a pili i ka pili ma ka pāʻani pili,11,12 ka nīnau no ke pili ana i nā cravings i ka maʻi o ka maʻi GD, e like me SUD, ʻaʻole i pane ʻia. ʻO nā mea koe i koe, ʻehā mai GD a hoʻokahi hoʻi mai AUD, ʻaʻole i loaʻa ka helu kikoʻī i kēlā me kēia maʻi i hoʻonohonoho ʻia a hōʻike i nā ʻano like ʻole o kēlā me kēia maʻi (e like me ke alualu ʻana i nā nalowale). Ke noho nei nā nīnau e pili ana paha i ka hoʻopili ʻana i nā pono o ka GD i ka hoʻohālike hou ʻana i ka hoʻokele SUD i maikaʻi no ka hoʻomohala ʻana i ka GD a no ka hoʻomanawanui ʻana o ka diagnostic i loko o ka pauku.

ʻO ke kuhikuhina

Hōʻike ʻo AUD i nā kiʻekiʻe prevalence kiʻekiʻe e pili ana i nā kūlana psychiatric ʻē aʻe. No kahi laʻana, ʻoi aku ka nui o nā ola a me nā makahiki o ka makahiki o ka AUD i mua o 30.3% a me 8.5%, kēlā me kēia, i ka National Epidemiologic Survey e pili ana i ka wai inu wai a me nā pili pili (NESARC).13 ʻOi aku ka nui o kēia mau pākuʻi ma mua o nā pā o ka lehulehu o nā DUD nontobacco (ʻoi loa: 10.3%, ka makahiki i hala: 2.0%) a me nā maʻi nui kaumaha (ola: 13.2%, hala-makahiki: 5.3%).13 Nā hualoaʻa mai nā ʻatikala i koho ʻia i ka lahui e koho ana i ka nui o ka lehulehu ma o ka GD me ~ 1% –2% e mau ana ka manawa a me ka hapalua o kēlā hui i nā makahiki i hala.14-17 ʻO nā wā ʻōpio, nā kāne male, ke kūlana socioeconomic haʻahaʻa, a me ke kūlana ʻole o ka mare ʻana (ʻo ia hoʻi, ʻaʻole i mare ʻia, ua hoʻohemo ʻia, hoʻokaʻawale ʻia, wahine kāne ʻole) ʻo ia nā mea maʻamau maʻamau e ka poʻe like me GD a me AUD / DUD.13,15-17

Kūʻai paila

I ka DSM-5, i hoʻoneʻe ʻia ka paepae diagnostic no GD mai ka ʻelima o nā ʻāpana he 10 i ka paepae o kēia manawa o ʻehā mau kūlike.1 Ke hoʻololi nei e nā DSM-5 Ua hoʻonohonoho ʻia nā pūʻulu hana ʻo SUD i nā helu GD e hōʻemi i ka hopena i ka nui o ka pā o ka wā hoʻokūkū aʻo ka hoʻomaikaʻi ʻana i ka ʻoiaʻiʻo diagnostic.18 Akā, ʻoi aku ka piʻi ʻana o ka uku o ka prevalence o GD e like me DSM-5 kūlike ʻia nā pono. No ka laʻana, ma kahi laʻana o nā poʻe nohoʻāina āpau o US (N = 2,417), ua piʻi ka nui o ka GD mai 0.1% a 0.2% e hoʻohana ana i ka DSM-5 nā kūlike.19 ʻO nā ʻatikala mai nā papa lāʻau lapaʻau e lawelawe ai i nā mea pīpī kiʻekiʻe. Hoʻonui ka hoʻonui ʻia o GD mai 81.2% ma lalo DSM-IV i ka 90.3% e hoʻohana nei DSM-5 nā loiloi ma waena o nā mea poʻe ʻoiʻo West Virginian (N = 2,750) e kāhea ana i ka laina kōkua kōkua pelekikena o nā mokuʻāina.8

ʻOiai ʻo ka paepae haʻahaʻa loa, e noho mau ana nā hōʻailona kūlike ma waena o SUD a me GD ma nā ʻōlelo o ka paepae diagnostic a me ka hoʻomaopopo ʻana i nā ʻano haʻahaʻa o ke ʻano.8,20 no ka mea, o ka DSM-5 Nā hōʻailona SUD, ka mea e hui pū ai DSM-IV mea hōʻeha a me nā mea hilinaʻi i loko o kahi hoʻonohonoho diagnostic hoʻokahi, ʻelua wale nō paha o hoʻokahi mauʻumekahi mau maʻi e koi ʻia no ka maʻi. Ua hōʻike ʻia ke kaumaha me nā maʻi ʻeha (2 – 3), hōʻeha (4-5 hōʻailona), a ʻeha (ʻeono a i ʻole kekahi mau hōʻailona) poʻe kikoʻī, ʻo ia ka poʻe me nā mea koʻikoʻi o GD. Nā hōʻailona 4), a me nā kaumaha (5-6 hōʻailona).

Inā hoʻohālikelike pono nā koina pono GD ma hope o nā hōʻike SUD me kona paepae haʻahaʻa, e piʻi nui ka nui o ka prevalence o GD, me kahi mea nui 2% o nā mea e hoʻōki i nā pilikia ʻoi loa i ka pili ʻana o ka poʻe pāʻani pili ola.14,15 ʻO ka noʻonoʻo ʻana i kēlā ʻano hoʻololi, ʻoiai inā he hopena kūpono paha i ka pae prevalence, hiki ke hoʻomaka ʻia inā he mau ʻākena i hōʻike ʻia ka maʻi subthreshold GD e hōʻeha i ka hōʻeha ʻana a i ʻole hōʻino ʻia i ka par me nā mea haʻahaʻa a me ke kālā AUD / SUD a inā lākou e pōmaikaʻi mai ka ʻike a me ka mālama ʻana. Nui nā noiʻi e hōʻike nei i nā hopena maikaʻi ʻole e pili ana i ka pāʻani subclinical, a me ka piʻi nui o ka comorbidity,6,21 nā pilikia kālā a me nā aie pili i pili kālā,8 a me ka hoʻomanala makua a me ka hoʻāʻo.7 Hāʻawi ʻia i kēia mau hopena koʻikoʻi, a me ka uku o ka comorbidity ma waena o AUD / DUD a me GD (i kūkākūkā ʻia ma ka māhele aʻe), ʻo ka hana mau ma waena o kēia mau papa hana kōkua e kōkua i nā kauka ma o ka hoʻopili ʻana i hoʻokahi hoʻonohonoho ponoʻī a me nā hoʻokiki koʻikoʻi ma waena o nā maʻi.

ʻO Comorbidity

ʻO nā maʻi āpau o GD a me nā psychiatric

ʻO ka comorbidity me nā maʻi psychiatric ʻē aʻe, me nā hui'ē aʻe, he mea maʻamau ma ka lua o AUD / DUD a me GD. ʻO nā hapa nui e like me ka 96% o nā poʻe me ke ola GD e hui pū nei i nā pono no ka liʻiliʻi ma kahi o ka maʻi psychiatric olawa kekahi.6,15 Ua hoʻonui ʻia nā kumukūʻai o nā maʻi he nui i nā maʻi psychiatric ma waena o ka poʻe me GD,16 me ka manaʻo (49% –56%)15,16 a me ke kaumaha (41% –60%)15,16 nā maʻi a me nā AUD (73%)16 a me DUD (38%)16 ka pālahalaha nui.15 ʻO nā maʻi pilikino ʻē aʻe kekahi i waena o ka poʻe me GD16 a ʻo ka lehulehu o nā maʻi comorbid lehulehu e hoʻonui ʻia. ʻOi aku kikoʻī, i ka hoʻopaʻa ʻāpana ʻāpana.15 na kanaka me GD he mau manawa 30 ka nui o ka nui (ʻekolu a ʻoi paha) mau maʻi psychiatric ola ʻē aʻe i hoʻohālikelike ʻia i ka poʻe me ka ʻole GD. Eia kekahi, ua hōʻike kēia haʻawina retrospective ka hapa nui o kēia comorbidity (74%) i mua a e lilo paha i mea pilikia loa no ka hoʻomohala ʻana o ka GD ma mua o ka lawelawe ʻana o ka GD i mea e pilikia ai ka hoʻomohala ʻana o nā maʻi psychiatric ʻē aʻe. Eia nō naʻe, ʻo ka lōʻihi o ka noiʻi loiloi.22,23 pono e hoʻokau waiwai pono no ka hoʻokumu ʻana i ka manawa pae kino o ka hoʻopilikia kino, e manaʻo ai e pili ana ʻo GD ka makahiki i hala me ka hoʻomohala hou ʻana o nā kūlana psychiatric hou e pili ana i ka manaʻo, ke kaumaha, a me AUD. Hōʻike ka pilikia o ke kūkulu ʻana i nā pilikia hou i ka paʻakikī o ka hoʻāhewa kālā,23 me ka poʻe papaʻi e pili ana i nā pōpilikia nui loa no ka hoʻomaka ʻana o kahi maʻi comorbid hou i hoʻohālikelike ʻia i nā mea ʻike pilikia a i ʻole mea hoʻohana ʻoluʻolu. Ma ka holoʻokoʻa, kākoʻo ke kākau moʻolelo i kahi pilina bidirectional e pili ana i ka comorbidity e like me nā maʻi psychiatric hiki ke lawelawe i nā mea pili i ka hoʻomohala ʻana, hiki ke lawelawe i nā mea mālama i GD, a hiki ke ala i ka hopena o GD.15,22,24

GD a me AUD / DUD

Ua paʻa maikaʻi ka pilina o GD me nā pilikia ʻē aʻe ʻē aʻe. ʻO nā koho hoʻohālikelike meta-kaila i koho ʻia e hōʻike nei i nā helu kiʻekiʻe o ke ola AUD a me ka DUD comorbidity ma waena o ka pilikia ola a me nā poʻe pīpī pathological, me 28% o nā poʻe pāʻani pāʻani e hōʻike ana i kahi AUD a me 17% e hōʻike ana i kahi DUD hewa.25 Hoʻomaopopo maikaʻi loa kēia mau pākuʻi e ka hoʻohālikelike ʻana i ka hopena o nā kumukūʻai o nā maʻi SUD / DUD ma waena o ka poʻe me ka ʻole o ka GD. Ma ke ano he, na Welte et al17 aʻo, 25% o ka poʻe me GD i hālāwai me nā koina no ka hilinaʻi ʻana i ka wai ʻona, akā ʻo 1.4% wale nō o ka poʻe me ka GD ʻaʻole i hilinaʻi i ka waiʻona. Ke hōʻike nei i ka kūkākūkā e pili ana i ka multi-comorbidity i hōʻike ʻia ma mua, ʻo ka loaʻa ʻana o nā maʻi hoʻonaninani pālua ʻelua, e like me ka concurrent AUD a me GD, pili me ka piʻi nui ʻana o nā maʻi psychiatric hou i hoʻohālikelike ʻia i mua o GD me ka ʻole o AUD.26

A ʻoi aku ka nui o nā mea maʻi a me nā poʻe mālama aʻoaʻo ma ke ʻano he lehulehu, a ʻo ka 41% ka nui o ka hālāwai hālāwai no ke ola ʻo AUD a me 21% ka manawa e hui ai no ka inu wai SUDs e pili ana i ka hilinaʻi nikotine.27 Hoʻopilikia ʻo Comorbid DUD i ka hopena o ka pili ʻana i ka poʻe i manaʻo ʻole i ka moʻolelo ola ʻo DUD he mau manawa 2.6 e hiki a hoʻokō i kahi mahina ʻo 3 a me ka malama ʻoihana hoʻohālikelike ʻia i nā poʻe me DUD.28 kekahi like29 ua ʻōlelo aku aia i waena o nā mea ola me AUD / DUD, ka hapa nui (58%) o ka poʻe e ʻimi nei i ka mālama pāʻani ʻana e hoʻohana pono ana i ka wai ʻona a i ʻole mau mea maʻi paha i ka makahiki ma mua o ka komo ʻana no ka mālama kālā. ʻO ka mea pōpilikia, ʻoi aku ka wai inu wai ʻona (ʻoi aku ma mua o 14 inu ʻawaʻawa / wiki a 4 / lā no nā kāne; ʻoi aku ka wai ma mua o 7 inu / wiki a ʻona paha 3 no nā wahine) e emi ana i ka wā o ka mālama pāʻani.30 a me nā hōʻemi pono ʻana i loko o ka hoʻohana ʻana i ka waiʻona e hoʻoikaika me ka hoʻopili ʻana o ka hoʻōla pōkole pōkole i loko o ka mālama kālā. Hiki i kēia mau hoʻomaʻamaʻa ke hōʻemi i ka hiki ke holomua i ka nui o ka hoʻokaʻawale ʻana i ka wai inu wai, ka nui o nā mea i hoʻopili ʻia me ka hoʻohemo ʻana i ka pāʻani.28 ʻO kēia mau loli like ʻole i ka inu ʻana i ka waiʻona a me ka petekuhi e hōʻike ana i kēia mau ʻano e alakaʻi i kekahi i kekahi manawa i ka manawa.

Hāʻawi ʻia i nā kiʻekiʻe prevalence kiʻekiʻe a me ka hopena o ka comorbid DUD a me AUD i nā hopena pili pili, ʻo ka hoʻopili ʻana a me nā kaʻina loiloi AUD a me ka DUD i ka hana lapaʻau e paipai ʻia no nā mea maʻi me GD. ʻO ke kalalā, ka nānā ʻana no ka pālepa pilikia ma waena o nā mea ʻimi lawehala me ka hōʻili ʻia o ka mea make, he mea ʻoiaʻiʻo hoʻi. Ma kahi kokoke, 15% o ka poʻe hulina lapaʻau ʻo AUD / DUD e hoʻokō nei i nā koina ola no ka GD a me 11% e hui nei i nā kūmole o kēia manawa no GD.31 I waena o nā mea maʻi opioid substitution, ʻoi aku ke kiʻekiʻe o nā maʻi o ka GD,31 a ua pili ka pilikia ʻo ka pili ʻana i ka hoʻopiʻi ʻana aku i ka hōʻino ʻana i ka lāʻau hōʻino ma waena o kēia mau mea maʻi.32 Hoʻohui maikaʻi ʻia ka hoʻohui ʻana ʻana o nā loiloi kālā a me nā kaʻina pili i ka hana hōʻino i nā mea pili kino wale nō, akā ʻaʻole hoʻi nā hopena lapaʻau o AUD / DUD. Eia kekahi, he nui nā poʻe me AUD / DUD e hiki ai ke hoʻokō ʻokiʻoki i ka waiwai a me ka lāʻau lapaʻau, akā hiki ʻole ke kāohi i kā lākou pāʻani i ke kīloi.29 ka manaʻo ʻana i nā lāʻau lapaʻau kūikawā a i ʻole paha i hoʻopili ʻia paha e pono no ka hoʻōla ʻana i nā maʻi ʻelua i nā ʻōnaehana hoʻoponopono hōʻona.

ʻĀhane GD

Hiki i ka mea nāna iho genetic ke hāʻawi i ka nui o ka pilikia i ka hoʻomohala ʻana o SUD a me GD. ʻO ka pāʻana o ka ʻano like ʻole e pili ana i nā mea genetic mai ka 0.39 no hallucinogens a i 0.72 no ka cocaine.33 Aia i ka mana o GD ma waena o kēia awelika ma 0.50-0.60 a ua like nō ia me nā helu mana o ka wai waiʻona a me nā opiates.34 Nā hana hana hou hope35 ma ka holomua mai ka hoʻomaka ʻana i ka addiction e hōʻike ana i ka nui o nā hoʻopili genetic i ka nui o nā hana ma hope o ke kaʻina hana hoʻomohala (ʻoiai, lilo ka mana)36,37 ʻO kēia mau mea nūhou e pili ana i ka hoʻololi ʻana i ka hopena no ka hoʻokumu ʻana i ka GD i hōʻike ʻia no ka 38% –65% o ka ʻano ʻokoʻa ka pili ʻana o ka lawena pilikia pilikia.38 a ke hōʻike nei i kahi mea nui i ka hoʻomaopopo ʻana i ka holo ʻana o kēia pilikia. Ua ʻike ʻia nā mea pono i loko o ke kaiāulu i kahi no ka pilikia o GD i ka maltreatment kamaliʻi,39 ka hele ʻana o ka mālama kālā a ka nānā ʻana i nā mākua,40-42 ʻĀpana ʻana i ka moʻomeheu,40 a me nā kūlana e like me nā mea kūpono o ka hoʻokumu ʻana i nā pāʻani pili a me nā ʻano makana.43

ʻO ka nui o ka hopena kūpono no ka hāʻawi ʻana i ka lāʻau lapaʻau he nonspecific a māhele ʻia i nā mea āpau. Loaʻa kēia hopena ʻokoʻa ma muli o nā pālahalaha ākea e like me ka impulsivity a me ka hopena maikaʻi ʻole, aia ka poʻe genetic underpinnings a lawelawe paha i nā mea pilikia no ka hoʻohana mea ʻana.44 ʻAʻole wale ka hopena pili i ka impulsivity a me ka hopena maikaʻiʻole e hōʻoki ʻia i nā mea hōʻino o ka hōʻino ʻana, akā ua hōʻike pū kekahi palapala puke burgeoning i kēia mau kumu i kumu no ka hoʻomohala ʻana i kekahi mau ʻano ʻē aʻe o waho, me ke GD.34,45 ʻO kahi laʻana, kahi holomua e aʻo ai i ka hoʻolālā24 ua manaʻo ʻo 1) i lalo o ka ʻōpio'ōpiopio i ka hoʻomohala ʻana ma hope o ka pili ʻana i ka pili pilikia a me nā ʻano depressogen, a ʻo 2 kēia mau mea ʻelua i hōʻike i kēlā me kēia e pili ana i kēlā me kēia ma waena o ka ʻōpio a me ka wā ʻōpio. Eia kekahi, no ka hoʻokolokolo ʻana i ka hoʻokolokolo me ka ʻike i kahi i loaʻa ai nā Taq A1 allele o ka wahine dopamine D2 polymorphism i pili me GD a me AUD.46 Ua pili kēia mea āpau me ka hoʻonui i ka impulsivity i nā hana neurocognitive,47 ke hōʻike nei i ka hiki i ka hapa ma waena o ka loli ʻano genetic ma waena o GD a me ka hilinaʻi waiʻona (12% –20%)48 ma muli o kahi genis predisposition e pili ana i ka lalo o ka impulsivity.

Lawe pū ʻia, loaʻa kēia mau ʻike i ke kākoʻo no ka hoʻohālikelike i ke ʻano o ka hoʻohui ʻana, ka mea e hoʻokaʻawale i nā mea like ʻole o ka addiction e māhele i nā diatheses core a me ka sequelae.37 ʻOiai ka hapanui o nā hopena hope (e laʻa, ʻaʻole i hoʻomalu ʻia ka pākeke ma mua o ka hoʻohana ʻana i ka heroin, ʻaʻole i hoʻohālikelike ʻia nā hana etiological he ʻano nui.49

Neurobiology

ʻO ke alahele mai ke ʻano o ke ʻano he hierarchical, hoʻihoʻi, a hoʻohuli ʻia i ka pae waena ma o ka neural circuitry, ua kūkulu ʻia ʻo ia ma o ka hana genetic a me ka hana e hoʻoponopono pono i ka hanana phenotypic. No ka laʻana, hoʻololi ʻia ke ala mesocorticolimbic dopamine i ka waiwai o ka waiwai o nā mea hoʻomohala a me nā ʻano.35 Kekahi mau haʻawina o GD a me DUD i hōʻike i ka hoʻopili genetic i nā ʻano like ʻole o kēia ala, me ka hoʻohui ʻana o nā mea hoʻokae a D2 a me ka nui o ka hoʻokuʻu dopamine, e wānana i ka pane hedonic kumuhana.50

E like me ka nui o nā hāʻawi i ke ʻano i ka lawenaʻa multifaceted, ʻo ke ʻano o ka hoʻohui i ke ʻano nui a hiki i ka hoʻopili ʻia e nā neurocircuit hoʻokahi. Nā kikowaena hou i komo i ke kaʻina hana hoʻohui hoʻohui ʻia ke ala nigrostriatal,51 ka koina hypothalamic-pituitary-adrenal (HPA),52 the insula,53 a me nā ʻāpana prefrontal cortex (PFC).54 Ma ke ʻano he ākea ākea o ka addiction, ʻo Koob a me Le Moal36 i waiho i ke ola o nā ʻelua o 1) i loko o nā ʻōnaehana neuroadaptations, i hōʻike ʻia e kahi paepae uku nui (ʻo ia hoʻi, ke ahonui) i hoʻopili ʻia e nā hoʻemi ʻana i ka hana dubamine ventral striatum, a me 2) ma waena o nā ʻōnaehana neuroadaptations. nā ʻōnaehana (e like me, HPA axis, hoʻonui amygdala) e hoʻonui hou ana, e hoʻohewa ai i kahi kūlana maikaʻi ʻole (ʻo ia hoʻi, hoʻoneʻe, craving) i ka loaʻa ʻole o ka waiwai / hana. ʻO kēia mau hoʻololi neuroadaptive e kūlike me nā ʻōiwi multistep o ka holomua i ka hoʻohui35 a hiki ke pākuʻi ʻia ma kahi hōʻeuʻeu o kahi spulsivity-to-compulsivity i kahi o ke komo mua ʻana i ke ʻano hana hoʻomohala hualoaʻa mai ka makemake makemake ʻole i nā hopena hedonic. ʻO ka hana ma hope aku e pili ana i ka hoʻomohala ʻana o ka hoʻomanawanui a me nā loli allostatic i ka neurocircuitry koʻikoʻi, a, ʻae me ka hoʻokaʻawale i ke kau mua ʻana, hele ʻia e ka hanana maʻamau, ʻāwili mau makemake e hoʻopiʻi i ka hopohopo a me nā hopena maikaʻi ʻole (ʻo ia hoʻi, hoʻemi i ka minamina, pale i ka haʻalele ʻana). Hōʻike ka hōʻike i ka lāʻau kūlohelohe e hōʻino i nā ʻoihana PFC i ka hōʻino no ka hoʻohaʻahaʻa kiʻekiʻe i ka hana, hōʻemi ka hiki ke hana i ka mana o ka inhibitory pono e hoʻomau i ka mālama.55 Hiki ke kōkua paha kēia hiʻona i ke kumu no ka mea e hiki ke hoʻomohala kekahi mau ʻano hana ma hope o ka pau ʻana o kahi ʻano hana hoʻomohala mua a no ke kumu e hoʻihoʻi ʻia ai ma hope o ka manawa o ka ʻāʻī ʻana.

ʻO Koob me Le Moal's36 hoʻohuli ʻia ke kumu hoʻohālike me ke kākoʻo no ka hoʻopili ʻana o ka stralatal ventral predominant ma mua o ka hoʻohana ʻana i ka lāʻau lapaʻau, ukali i ka hoʻonui ʻana o ka modus striatum dorsal e like me nā cues conditioned e hoʻomaka i ka hāʻawi i ka uku hedonic ma ke kumu hoʻohālike nui o ka hanana.56 Ma kēia ʻikepili, ʻike ka minamina i nā mea minamina ma hope o ke ʻano he mau manawa o ka cory sensory (e laʻa, ke ʻano "pssht" o kahi pia) a me nā ʻano hana hoʻohālikelike (e laʻa, ka inu ʻona), ma o ke kaʻina hana o ke ʻano hanana. ʻO ka hopena, kahi o ka attenuation o nā moku aversive (e laʻa, cravings, withdrawal) pili i ka ʻano hana addictive lilo i alakaʻi ikaika no ka hoʻomau ʻana i ka hana. ʻO ka mea mahalo, ʻo ka hōʻino i kahi subregion o ka insula, ke kuleana no ka loiloi ʻana i ka ʻano o loko a me ka ʻike naʻau.57

Hoʻohui i ka insula, kahi ʻōnaehana neurobiological pono nui o ka ʻōnaehana anti-reward ʻo ka axis HPA. Hoʻopili ʻia kēia ala neuroendocrine me ka hōʻike maʻamau i nā mea e komo ai, a i ka wā o ke komo ʻana i ka pāʻani.58 e hoʻohuli ana i kona hiki ke hana pono a maikaʻi.52 ʻO nā hoʻololi i ka koena HPA ka hopena o ka hoʻohana pinepine ʻana i ka nui o ka hoʻonui i ka neʻe ʻana o ka hormone adrenocorticotropic a me corticosterone. Ke hoʻolilo nei kēia mau loli i ka poʻe i hiki ke hōʻeha i ka kaumaha ma mua o ka manawa ʻē aʻe36 a alakaʻi i kahi hoʻonui lōʻihi i kā lākou hikiʻole i nā hopena maikaʻiʻole o ke kaumaha.59 Eia kekahi, ua noʻonoʻo ʻia kēlā mau hoʻololi i ke koena HPA ma waena o nā ʻōnaehana hoʻohālikelike i ka pōkō o ke kaʻina hana, no ka mea, ʻo ka loaʻa ʻana o kēia ʻano pane ʻana i ke ʻano o ka mea e hopohopo i ka ʻike o ka moʻolelo a me nā wānana hoʻi ka hoʻohuli.59

ʻOiai ʻo Koob lāua ʻo Le Moal o36 ua hoʻohālikelike ʻia ke kumu hoʻohālike e pili ana i nā mea kū, e ulu ana nā hōʻike hōʻike e pili ana i nā hana paʻa i komo pū ʻia me ka hilinaʻi nui o ka GD. ʻO kahi laʻana, ʻo ka impulsive-compulsive shift spectrum e kū nei i DUD e hana nei ma GD.60 Hoʻohui, ma ka pae molekula, hōʻike ke hōʻike i nā dopamine D2 receptors e hoʻomau i ka ʻike o ka uku hoʻonaʻauao ma o ka pili āpau.61 a me ka lako hana.62 No ka mahalo i ka manaʻo dopaminergic e pili ana i ka GD, dopamine agonists, hoʻohana pinepine ʻia e like me ka laikini ʻo ka poʻe maʻi me ka maʻi Parkinson a me ka pale ʻole ʻana i ka maʻi wāwae, hiki ke alakaʻi i ka hoʻopono ʻana i ka ʻano hedonic e like me ke hypersexuality a me ka petekee, ostensibly ma o disregulation o ke ala uku dopamine.63 ʻO kaʻoiaʻiʻo, nā lāʻau lapaʻau me nā antagonist dopamine i hōʻike i kekahi hana pono ma ka mālama ʻana i ka hilinaʻi o ka waiʻona.64 ʻoiai, ʻaʻole naʻe i kākoʻo ka hōʻike ʻana i ka pono o kēia ala i ke GD.65,66 ʻO ka mea hope loa, e like me DUD, ka hiki ʻole o nā poʻe me GD ke hōʻike i nā mana kūpono o ka mana o ka hoʻopulapula e hiki ke hele mai i nā hui pū ʻana o ka ulu ʻana o ka hoʻouka ʻana i ka papa hana hoʻoweliweli i ka wā o ke pāʻani.67 i hui pū ʻia me nā ʻōnaehana koʻikoʻi hyperactive,58 me ka hoʻemi ʻana o ka hoʻōla ʻana i nā ʻoihana PFC koʻikoʻi.68

ʻOiai ka holomua nui o ka wehe ʻana i ka mana o ka neurobiological i ʻelua o GD a me DUD, nui ka hana e hana ʻia. ʻOiai ua hana ʻia nā kuhi i ka hoʻohui ʻana i ka GD i loko o nā hiʻohiʻona preexisting o DUD, ke nele nei ka palapala GD i ka hoʻomaopopo piha ʻana a me ka hohonu no ka hana o ka dopamine i ka hoʻolālā ʻana o ka haunaele, ka mea e pale ai i kona komo piha ʻana i kēia mau hiʻohiʻona ākea o ka hoʻohui . ^ E Ha yM.35-36 Eia kekahi, ua maopopo ka piliʻana o ka neurotransmitters mai kahi dopamine i ka nui o ka hoʻouka ʻana,54 akā, ʻo nā hōʻike empirical e pili ana i ka serotonin, norepinephrine, a me ka glutamate i GD he sparse.69

Neurocognition

ʻO nā maʻi hoʻohui hoʻohui e pili pū me nā hemahema cognitive, ʻoiai he nui ka mana ʻē aʻe i nā hopena i nānā ʻia e pili ana i ka waiwai i hōʻino ʻia, me ka ikaika a me ka paʻakikī o ka hoʻohana. I loko o nā kānaka me ka inu ʻona, loaʻa nā deficits i nā kīʻaha o nā hana mana (EFs) a me nā mākau visuospatial, ʻoiai nā mea ʻē aʻe e like me ke ʻano ʻōlelo a me ka mana motor gross spally spared.70 ʻO ka mea pōmaikaʻi, ʻo kēia mau hopena i hopena mai ka hoʻohana i ke aʻalolo hiki ke liʻiliʻi loa i ka hapa ʻokoʻa me ka pau mau loa. Hōʻike ka poʻe kūʻokoʻa me GD i nā hemahema i EFs,71 e pili ana i ka hoʻoholo 'ana,72 pale pale73 a me ka noʻonoʻo;74 akā naʻe, ʻaʻohe ʻike o nā noi i kēia manawa i ka hopena o ka haʻalele mau ʻana i ka pāʻani ʻana ma kēia mau kīnā ʻole. ʻO kekahi nīnau hou ʻole i hoʻopuka ʻia ma kēia puke e pili ana inā pili kēia mau neurocognitive deficitits i mua premorbidly a i ʻole e hōʻike ana i nā hopena iho i nā hopena phenotypic o nā loli physiological ma muli o nā ʻano hoʻohālikelike. Nui nā mau noiʻi i ka GD a me ka hilinaʻi waiʻona e kākoʻo pinepine ana i ka imporbivity premorbid ma ka nui o ka lehulehu o nā mea me ka hoʻohui, ʻoiai ka ʻike o kēia mau noiʻi e hōʻike ana i ka nui o ka hōʻemi i nā EFs e like me ka hana hoʻomanaʻo ʻana i waena o nā poʻe me ka hilinaʻi ʻākina i hoʻohālikelike ʻia i ka poʻe me GD.75 manaʻo paha e hoʻopili ai ka ethanol ingestion koho i ka hoʻopale ʻana i ka circuitler PFC. Eia kekahi, hoʻohui me nā ʻike neurocognitive, hōʻike hōʻike hōʻike pilikino i ka hiki ke hoʻokiʻekiʻe ʻia i ka lekiō i ka GD, e hāʻawi ana i nā kūʻokoʻa kūʻokoʻa, multimodal no ka pale ʻana i ka pale o ka pale a me ka hōʻeha i ka hoʻoiho.73,76

ʻO ka holoʻokoʻa, nā ʻike e pili ana i ka hemahema o ka neurocognitive ma GD, akā, e pili ana i nā noiʻi i hoʻohana ʻia ai ke GD ma ke ʻano he hana hoʻohālike no ka hoʻohui ʻana i nā wahi noiʻi.75 Eia nō naʻe, kahi hana koʻikoʻi i hoʻomau ʻia i loko o kēia mau puke he heterogeneity i loko o nā hana cognitive i lawelawe ʻia ma nā noiʻi noiʻi, ka mea e kaupalena ana i nā hoʻohālikelike pololei a me nā loiloi hoʻohui.77 ʻO ka mea nui, aia kēia laina o ka noiʻi i loko o kona wā kamaliʻi, a me ka hoʻomau ʻana i ka hoʻomohala ʻana, hiki ke hoʻohālikelike ʻia ka hoʻopiʻi pono ʻana o ka hoʻopiʻi neurocognitive ma waena o nā mea kū hoʻokahi me GD a me nā mea e hōʻino maikaʻi ʻole i nā mea like e like me ka waiʻona. Hoʻoulu i nā ʻike ʻike ma nā hana like a me ke komo ʻana i ka hoʻolālā lōʻihi lōʻihi74 e hoʻokūʻē i kā mākou ʻike i ka impulsivity a me nā mea hana cognitive koʻikoʻi inā e pili ana i ka GD a me DUD.

lapaʻau

Ma kahi o kahi hapakolu o nā poʻe me ka GD a ma kahi hapaha o kēlā me ke kūpaʻa waipiki e ola maoli nō me ka ʻole o ka mālama ʻana.78,79 E huli aʻe kekahi i nā koho lapaʻau e komo pū me ke kōkua pilikino a me ke kākoʻo ʻana i ka pōkole, ka pōkole pōkole a me ka hoʻoweliweli, a me ka mālama ʻana o ka cognitive-behavioral (CBT) i mea e hōʻea hou ai i kā lākou ʻano hoʻomālamalama. Kahi ʻia kēia mau mea loiloi i kēlā mau mea i kūkulu ʻia no ka ʻawaʻawa a me nā mea inu lāʻau, a e noiʻi ana noiʻi e pili ana i ka poʻe ʻōpena,80 e like me ka poʻe me nā mea e pili ana i ka waihona,81 pōmaikaʻi ʻia mai loko mai o ia ʻano. Akā naʻe, ʻaʻole i ākea ka mālama ʻana i ka mālama kālā. Ma kēia ʻāpana aʻe, kūkākūkā puʻikepili mākou i nā mea maʻamau no ka pilikia o nā waiwai a me nā kīʻaha.

12-Kūleʻa papahana

Alcoholics Anonymous (AA) he hui kākoʻo a kahi poʻe i aloha ʻia no ka poʻe me nā pilikia wai. Loaʻa ka lehulehu o nā hālāwai ma ʻAmelika a hōʻike ʻia e ka noiʻi he mea maʻamau ke komo ʻana a pili i nā hopena i hoʻomaikaʻi ʻia. Kelly et al82 a hahai i nā mea maʻi kūloko o ka waiʻona i paipai ʻia e komo i nā hui kākoʻo e like me ka hoʻokuʻu ʻana mai ka maʻi outpatient intensive a ua loaʻa ka 79% i kēia mau hui i ka makahiki mua. Ua emi ke komo akā ua noho nui ma ka lua (54%) a me ke kolu (54%) mau makahiki ma hope o ka hoʻokuʻu ʻana a ua pili ʻia me ka hopena maikaʻi ʻana o ka inu. ʻO nā haʻawina ʻē aʻe83,84 Manaʻo e loaʻa paha nā pōmaikaʻi o ke komo ʻana o ka AA i ka wā e komo ai nā mea maʻi i ka hui pū ʻana me AA me ka mālama ʻana i nā ʻoihana loea a hiki i ke komo ʻana o AA i mea nui nui i ke ola lōʻihi.

Kuhi ʻia ka poʻe Gamblers he mea inoa ʻole (GA) ma ke ʻano he kiʻina 12 i pae ʻia e AA, a ua ʻike ʻo ia i nā loina he nui i loaʻa i loko o ʻAi, me ka hoʻohui wale ʻana, ʻo ka hoʻohana ʻana i ka laʻa maʻi o ka hoʻohui ʻana, a me ka noʻonoʻo pono i ka hoʻohui ʻana ma ke ʻano he maʻi mau maʻi. Loaʻa ʻo GA i ka pōmaikaʻi i ka poʻe me ka ʻoi aku ke kaumaha nui,85 akā, nā hiʻohiʻona i hōʻike ʻia (e like me, abstinence orientation) e hōʻemi i kāna hoʻopiʻi no kekahi poʻe. Aia kahi liʻiliʻi o ka ʻike ma ke ʻano he lawelawe kūʻokoʻa ʻo ia, akā ʻike nā haʻawina85-87 manaʻo e hoʻopōmaikaʻi nā pōmaikaʻi o GA ma ke ʻano he kū hoʻokahi wale nō paha, e like me ka hopena o nā kumukūʻai kiʻekiʻe. Eia nō naʻe, ʻo kahi komo ʻana o GA i ka hui pū ʻana me ka mālama loea e like me ka hoʻomaikaʻi ʻana i nā hopena hopena,88 a ua waiho mau ʻo ia i nā papa hana i hoʻolako ʻia e kekahi o nā ʻoihana i hoʻomaʻamaʻa ʻia.89

Kokua kōkua iho

Hāʻawi ʻia nā mea kōkua pilikino i nā pono he nui i loaʻa ʻole ma 12 a i ʻole hālāwai a hoʻokele e haʻi ʻia e like me ke pilikino, mālama kālā, ʻoluʻolu a me nā ʻoluʻolu.90 Hoʻolaha ka puke ʻo ka maʻi puke ʻana no ka pilikia o ka waiʻona me ka nui o ka liʻiliʻi me ka nui o ka hoʻopiʻi ʻana i ke ʻano o ka mālama ʻana, ʻaʻole paha e like ia me ka nui o ka nui o ka wawa ʻana, a ʻike ʻia e alakaʻi pono ai ka mālama ʻana o nā mea mālama i nā wā lōʻihi.91 Ua loiloi ʻia ʻo Bibliotherapy no ka pili ʻana i ka pilikia pilikia a ua pono ia no nā mea pāʻani e pili pono ana i nā mea hana pila e kali i ka papa inoa.92 Eia nō naʻe, kahi hoʻokolohua paʻa i hoʻopaʻi ʻia (RCT)93 a me kāna hana ukali 24-mahina94 manaʻo e hiki ke hoʻopaʻa ʻia ʻo ka mea lapaʻau i mea nui no ka bibliotherapy pono no ka pilikia o ka pāʻani pili.

Hoʻolako he kumu

Hiki ke koho pono ka lūlū ʻana no nā poʻe me nā mea hoʻohui ʻē aʻe e pili ana i ka loli ʻana a i ʻole e ʻimi ai i ka mālama ʻana. Meta-analiona o 55 randomized a quasi-randomized Studies Ua hōʻike i ka interventions interventions no ka poʻe me AUD / DUD alakaʻi i ka nui hōʻemi o ka inu ʻana i ka wai a me nā hopena o nā waiwai i pili i nā no ka mālama ʻana i ka hopena a me nā hopena hoʻohālikelike i nā hopena lāʻau ʻē aʻe.95 Pēlā nō, loaʻa nā papa hana hoʻoweliweli i kahi mākaʻikaʻi maikaʻi no ka pilikia o nā mea pāʻani. Ke hōʻike nei kahi RCT i hiki ke hoʻopau ʻia nā manawa hoʻonaninani hoʻokahi o nā minuke 75 i waena o nā mea pāʻani pilikia ma ka hōʻemi ʻana i ka pīpī pākēkē a me nā mea kālā ke hoʻohālikelike ʻia i ka ninaninau hoʻokele, me nā hopena e hoʻomau a hiki i hoʻokahi makahiki ma hope o ka wawao ʻana.96 Nā pepa kikoʻī hou aʻe (e hoʻohālike, 10-15 mau minuke), me nā ʻōlelo aʻoaʻo pōkole a me nā ʻōlelo pilikino, e hōʻike ana i ka hoʻohiki no ka hoʻololi ʻana i kekahi mau lawena lawena i ka poʻe me ka pilikia a i ʻole ka hoʻokaʻawale papaʻa.97,98 ʻO ka mea kupaianaha, ʻoi aku ka nui o nā hoʻopiʻi (ʻoi aku, ʻehā mau manawa) o ka hoʻoikaika hoʻoikaika ʻana i hui pū ʻia me CBT, ʻaʻole i hoʻomaikaʻi pinepine i nā hopena i pili ʻole i nā palapala pōkole a ʻōlelo wale nō i loko o RCTs o nā poʻe me ka pilikia a i ʻole ka hoʻokaʻawale ʻana i ka pāʻani holoʻokoʻa mai ke kaiāulu98 a me kamela haumana99 nā iwi. Hiki i kēia hopena ma muli o ka hoʻopili ʻana o nā poʻe ʻōpio subclinical i kēia mau noiʻi, ʻaʻohe mea pono ʻole a makemake paha i nā mea lapaʻau nui. No nā mea ʻē aʻe, ʻo ka poʻe me GD, ʻoihana e hāʻawi ʻia e ka ʻoihana loea i ka lōʻihi o ka lōʻihi e pono ai no ka loli ʻana o ka hewa.

He Cognitive a me / a me nā hanana ʻaʻano

Hāʻawi ʻia ka ʻoihana aloha, hoʻomaikaʻi ʻia ʻo CBT i nā hopena e pili ana i ka pili o GA a i ʻole bibliotherapy i alakaʻi ʻia i loko o ka poʻe me GD i RCTs.86,88 Akā, ma kahi RCT100 ua komo i loko o nā poʻe loea haumāna haumāna koloka ʻoi, kahi kūlana 4- a hiki i ke kūlana 6-session CBT i hōʻea i nā hopena maikaʻi aʻe e pili ana i ka hālāwai hoʻokahi o nā manaʻo pane pilikino. ʻO nā ʻikepili ʻē aʻe e nānā ana i nā ʻano hoʻohālikelike (pūʻulu hoʻohālikelike i kekahi kanaka) a i ʻole nā ​​hoʻohālikelike o ka CBT i nā ʻimi ʻē aʻe i ʻike pinepine ʻole i kekahi ʻokoʻa i waena o nā hui hoʻohālikelike.101-103 Hōʻike kēia mau hōʻike i ka hōʻike ʻana mai i ka pili ʻana o ka waiʻona.104

ʻOiai ʻo CBT no ka pili ʻana, ua like like me CBT no ka mālama kino ʻana i nā lāʻau, ʻike ʻia nā maʻi cognitive e pili pono ana i nā kuhi kuhi e pili ana i ka pili ʻana i ka pili ʻana i nā mea ʻokoʻa. Hoʻokomo pinepine kēia mau ʻenehana i nā mea lapaʻau hou aku (ʻo ka laʻana, a hiki i nā hālāwai 20) a hōʻike i nā pōmaikaʻi maikaʻi e pili ana i nā mana o ka papa inoa.105,106 Eia nō naʻe, pono e hoʻopili ʻia kēia mau hopena me ka hoʻohana ʻana i nā ʻāpana nui a me ka hoʻohana ʻana i nā loiloi intact-to-fitsaboana, e like me kēia mau noiʻi105,106 hoʻokaʻawale i nā poʻe i haʻalele i ka hana e hopena i nā hopena lapaʻau hopena. Hoʻohālike i nā haʻawina ʻē aʻe e loaʻa ana i nā ʻokoʻa ʻē i waena o ka mālama ʻana i nā mea pāʻani.101 he RCT107 ka hoʻohālikelike i ka therapy cognitive i nā lāʻau lapaʻau hou (e like me, ke kaukauanʻi ʻana, ʻano hana hoʻonaninani) a me nā loiloi manaʻo-i-lapaʻau ʻia ʻaʻole i loaʻa he mau ʻokoʻa o ka hopena o ka pili ma ka ʻoihana.

Ma kahi holoʻokoʻa, ʻo AUD / DUD a me ka noiʻi ʻoihana pili i kēia wā e hōʻike ana ʻaʻohe ʻano kūpono ʻole a i ʻole ke ala kūpono. Ka mea, i ʻike ʻia he maikaʻi loa ka mālama ʻana, me ka liʻiliʻi ʻole i ʻike ʻia ma waena o nā hana hoʻoikaika i ka wā e hoʻopiʻi ʻia ana kekahi i kekahi. Pēlā ka poʻe me nā mea hoʻohui e makemake nei i ka mālama ʻana i nā koho ākea e loaʻa iā lākou e pili ana i nā makemake, nā pono, a i ʻole ka pohō o kā lākou hūnā. Ke neʻe nei i mua, hiki i nā lāʻau ke hoʻomaka me ka hoʻopili ʻana i nā ʻike e kamaʻilio ai i ka comorbidity kiʻekiʻe ma waena o GD a me nā maʻi psychiatric ʻē aʻe, e pili ana i ka hopohopo, ke kaumaha, ka pilikino, ka waiʻona, a me nā mea inu.22 Hōʻike ka hōʻike hōʻike e pane i nā hōʻailona psychiatric a hoʻomaikaʻi i ka wā mālama ʻoi pū.108 Eia nō naʻe, ke noho nei ka lumi no ka holomua hou ʻana o nā maʻi psychiatric i waena o ka poʻe i hōʻike ʻoi aku ka pilikia.109 e manaʻo nei e pono i kēia mau kānaka ke ʻike i ka ʻike a me ka hoʻopili e hoʻoponopono i nā kūlana comorbid.

Panina

ʻO kahi pilikia nui i ka hoʻopili piha ʻana i nā loulou a me nā pilikia ma ka GD a me AUD / DUD e pili ana i ke ʻano asymmetrical o ka noiʻi i nā pilikia pili i kahi mea pili i ke kaukaʻi.110 Eia nō naʻe, ua hoʻomaka nā noiʻi hou e wehe i ka holomua o GD.111 e ʻōlelo ana he paʻakikī o ka etiology o GD, a he epigenetic, a ua komo pū me ka nui o nā mea wānana proximal a me ka mamao. Eia kekahi, ʻano like kēia mau hiʻohiʻona i nā hiʻohiʻona psychopathology hoʻomohala o AUD / DUD, e hōʻike ana i ka overlap nui a me nā mea maʻamau. Ke hōʻiliʻili nei nā hōʻikeʻike, hiki iā mākou ke hoʻohui i nā makahiki o nā noiʻi i nā pālahalaha nui e hoʻopili ʻia ana i ka hoʻohui ʻana37 e hoʻohui i nā hoʻohui hoʻohālikelike e like me GD.

Ke noiʻi nei i ka nīnau ʻana i nā nīnau e like me nā pōʻino a me nā kumukūʻai ʻoihana e pili ana i ka pāʻani subclinical a i ʻike paha nā poʻe lawaiʻa subclinical i nā hopena maikaʻi loa e pili ana i ka hoʻopiʻi ʻana i nā palapala diagnostic o AUD / DUD. He mea nui kēia mau haʻawina no nā loiloi DSM e pili ana i nā hoʻoholo e pili ana i ka hoʻohālikelike ʻana i nā koina pono GD a me nā paepae kokoke loa i kēlā no AUD / DUD. ʻO kekahi mea noiʻi mua mua o ka noiʻi ʻana i nā loiloi o nā hana lapaʻau, aʻo nā mea kūpono e hoʻopili ʻia ana e pili ana i nā maʻi comorbid a i ʻole a i lalo o nā hana kuhi manuahi (e laʻa, impulsivity). ʻO ke kumukūʻai kiʻekiʻe o ka comorbidity e hōʻike nei i kēlā me kēia hoʻopihapiha hoʻopihapiha he wahi o ka mea pono nui a he mana nui loa. ʻO ka mea pōʻino, ʻoi aku ka maikaʻi o ka puke ʻana o ka palapala noi ma GD ma kēia e keena.

Ma nā ʻōlelo lapaʻau o ka hana lapaʻau, hōʻike mākou i ka nānā ʻana no nā maʻi psychiatric no ka pāʻani ʻole i waena o ka poʻe e ʻimi nei i ka mālama ʻana no nā pilikia ʻoi. ʻO ka nānā ʻana i nā hana maʻamau no ka maʻi psychiatric ma waena o nā mea pīpī e noi ana i ka poʻe maʻi e kōkua i kēia mau mea maʻi e loaʻa ai ka mālama ʻana no ka maʻi comorbid wikiwiki a hiki i ka hoʻomaikaʻi ʻana i ka pane ʻana i ka GD a me ka hōʻeha comorbid i ka wā e hoʻolako ʻia nei nā hana like me ka manawa a me ka hoʻopili ʻana. Eia kekahi, i loko o nā haukapila lapaʻau ʻo AUD / DUD, ʻoi aku ka nui o ka mālama ʻoihana kīlepa ma loko o kēia heluna e hoʻihoʻi ana i ka nānā ʻana i nā ʻōnaehana pono no ka pili ʻana i nā pilikia petipapa.31,112

ʻO GD, e like me ka mea e pono ai ke kuhi ʻano nonsubstance mua, e kau ana i ka pahu no ka noʻonoʻo ʻana i nā maʻi ʻē aʻe e like me ka mea e pili ana i ka hoʻomau i ke ʻano i ka wā e hiki mai ana. E like me ka loiloi ʻana, hōʻike like ʻo GD i nā hiʻohiʻona nui ma waena o nā kāʻei āpau me AUD / DUD, e alakaʻi nei i kekahi mau mea noiʻi37 e pili i kahi laʻana o ka hoʻohui ʻana, e hōʻike ana i ka uhi ʻana etiological ma waena o nā hōʻike like ʻole o ka addiction (e hoʻohālike, ka papaʻa ʻole ʻana, ka hoʻohana ʻana i ka wai, a me ka hoʻohana ʻana i ka cocaine). Pono ka poʻe noiʻi a me nā mea lapaʻau e pili pono i ka nui o ka noho ʻana i kēia mau kūlana i ka wā e noʻonoʻo ai i ka psychopathology no nā ʻano like ʻole o ka hoʻolālā ʻana i nā noiʻi noiʻi, loiloi no ka tohu simatology, a me ka hoʻolālā ʻana i ka mālama ʻana.

mau hoomaikai ana

Ua kākoʻo ʻia ka hoʻomākaukau ʻana o kēia hōʻike i nā ʻāpana a NIH: P60-AA003510, R01-AA021446, R21-DA031897, R01-DA-033411-01A1, a he National Center no ka hāʻawi ʻana i nā pāʻani pāʻani maʻa.

ke kaikoeke

ʻAʻole ka'ōlelo a nā mea kākau e pili ana i ka paʻi nuiʻole i kēia hana.

 


E hoʻomaopopo '

1.ʻAlaʻAmelika PōʻokoʻaʻAmelika. Ka Papa Hana Hoʻonaʻauao a me Heluhelu o nā Mino Lō. ^ E Ha yM. 5th ed. Wakinekona, DC: ʻAmelika Hui Pū ʻIa ʻAmelika, 2013.
2.Lesieur HR, Rosenthal RJ. Pāʻani palapala: ʻo ka loiloi ʻana o ka puke (i hoʻomākaukau ʻia no ka American Psychiatric Association Task Force ma ke Komite DSM-IV e pili ana i nā maʻi o ka hoʻokuʻi ʻole i hoʻokaʻawale ʻia i nā wahi ʻē aʻe). J Gambl Stud. 1991;7(1):5–39.
3.Schuckit MA. Ke koki Lunahooponopono: DSM-5 - mākaukau a ʻaʻole paha, ma aneʻi e hele mai ana. J Stud Laloila i ka waiona. 2013;74(5):661–663.
4.Weinstock J, Burton S, Rash CJ, et al. Nā mea wānana e pili ana i ka mālama ʻana i ka hana hoʻokaʻawale pilikia: ka ʻikepili mai ka West Virginia Gamblers Help Network. ʻO Psychol Addict Behav. 2011;25(2):372–379.
5.Weinstock J, Scott TL, Burton S, et al. ʻO kahi manaʻo hoʻomōhala o kēia manawa i nā mea pāʻani i ke kāhea aku i kahi mea kōkua. ʻO Addict Res Theory. 2014;22(5):398–406.
6.ʻO Bischof A, Meyer C, Bischof G, Kastirke N, John U, Rumpf H. Comorbid Axis I-pilikia ma waena o nā kumuhana me ka pathological, problem, a i ʻole ka hopena hoʻoliʻelima i hōʻuluʻulu ʻia mai ka lehulehu ma Germany: nā hopena o ka hōʻike PAGE. ʻO ka hauā hau. 2013;210(3):1065–1070.
7.ʻO Moghaddam JF, Yoon G, Dickerson DL, Kim SW, Westemeyer J. Suicidal no ka manaʻo a me ka hoʻāʻo i ka makeʻe i loko o nā pūʻulu ʻelima me nā ʻano like ʻole o ka pāʻani: nā ʻike mai ka National Epidemiologic Survey e pili ana i ka mea inu wai a me nā kūlana pili. Am J Addict. 2015; 24: 292-298.
8.Weinstock J, Rash CJ, Burton S, et al. ʻO ka huli ʻana o ka DSM-5 i hoʻololi ʻia i ka pā pāʻani pathological i kahi hōʻike helpline. J Kaukaʻi Kauka. 2013;69(12):1305–1314.
9.Morasco B, Weinstock J, Ledgerwood LM, Petry NM. Nā hiʻohiʻona noʻonoʻo e hoʻolalelale ana a pale aku i ka palaka papa. Cogn Behav Prac. 2007; 14: 206-217.
10.Tavares H, Zilberman ML, Hodgins DC, el-Guebaly N. ʻO ka hoʻohālikelike o ka makemake ʻana ma waena o nā mea pāʻani pathological a me nā mea inu wai. Ka Waiʻona Clin Exp Res. 2005;29(8):1427–1431.
11.ʻO Ashrafioun L, Kostek J, Ziegelmeyer E. Ke koi nei i ka makemake o ka hōʻike post-cue me kona hui me ka nui e holo ana i kahi hana koho koho. ʻO J Behav Addict. 2013; 2(3):133–137.
12.WIH opio, Wohl MJA. ʻO ke Kōmike Kuhi Kumuhana: hōʻoia i ka psychometric a me ka hopena o ka hana. ʻO Psychol Addict Behav. 2009;23(3):512–522.
13.Hasin DS, Grant BF. ʻO ka National Epidemiologic Survey e pili ana i ka wai inu wai a me nā mea e pili ana (NESARC) Waves 1 a me 2: ka nānā ʻana a me ka hōʻemi o nā ʻike. ʻO Soc Psychiatry Psychiatr Epidemiol. ^ E Ha yM. Epub 2015 Iulai 26.
14.Gerstein D, Volberg RA, Toce MT, et al. Pāʻani hoʻomaʻamaʻa a me ka hoʻomaikaʻi ʻana: Hoike i ka National Gambling Impact Study Commission. ^ E Ha yM. Chicago, IL: National Opinion Research Center, 1999.
15.Kessler RC, Hwang I, LaBrie R, et al. ʻO ka palaki a me ka hoʻoponopono ʻana i ka pā pāʻani pathological DSM-IV i ka National Comorbidity Survey Replication. Psych Med Med. 2008;38(9):1351–1360.
16.Petry NM, Stinson FS, hāʻawi ʻo BF. Comorbidity o DSM-IV petological gaming a me nā maʻi maʻi ʻē aʻe: nā hopena mai ka National Epidemiological Survey e pili ana i ka waiʻona a me nā kūlana e pili ana. Ka Haumānaʻo J Clin. 2005; 66: 564-574.
17.Welte J, Barnes G, Wieczorek W, Tidwell MC. Alika a me nā kulekele papaʻaina ma waena o nā pākeke US: prevalence, demographic pattern and comorbidity. J Haawina Alakona. 2001; 62: 706-712.
18.Petry NM, Blanco C, Auriacombe M, et al. ʻO kahi ʻike e pili ana a me ka hoʻolilo ʻana i nā hoʻololi i manaʻo ʻia no ka papaʻa pathological ma DSM-5. J Gambl Stud. 2014; 30: 493-502.
19.Petry NM, Blanco C, Stinchfield R, Volberg R. ʻO kahi loiloi empirisical o nā hoʻololi i manaʻo ʻia no ka maʻi hoʻonaninani ma ka DSM-5. lama. 2012; 108: 575-581.
20.Weinstock J, Rash CJ. Nā maʻi lapaʻau a me nā noiʻi pili ʻana i ka pilikia o ka pāʻani ma DSM-5. Curr Addict Rep. 2014; 1: 159-165.
21.Brewer JA, Potenza MN, Desai RA. ʻO ka hoʻokaʻawale ʻokoʻa ma waena o ka pilikia a me ka pāʻani pathological a me nā maʻi psychiatric i loko o nā poʻe me kaʻole a me ka ʻole o ka hōʻemi a me ka hilinaʻi ʻole ʻia. CNS Spectrum. 2010; 1: 33-44.
22.Chou KL, Afifi TO. Ke hōʻole ʻia (pathological a i ʻole pilikia) pāpaʻi a me ke koikoi ʻO ka maʻi psychiatric: nā hopena mai ka National Epidemiological Survey e pili ana i ka mea inu wai a me nā kūlana pili. ʻO'Am Epidemiol. 2011;173(11):1289–1297.
23.Parhami I, Mojtabai RM, Rosenthal RJ, Afifi TO, Fong TW. Ke pāʻani nei a me ka hoʻomaka ʻana o nā pilikia noʻonoʻo noʻonoʻo comorbid: kahi loiloi lōʻihi ka loiloi ʻana i ka paʻakikī. J Kauahi Hoike J. 2014; 20: 207-219.
24.Dussault F, Brendgen M, Vitaro F, Wanner B, Tremblay RE. ʻO nā loulou lōʻihi ma waena o ka impulsivity, nā pilikia pili kālā a me nā hōʻailona kaumaha: he kumu transactional mai ka wā ʻōpio a hiki i ka wā ʻelemakule. J Kaukaʻi Kauka Keiki J. 2011; 52: 130-138.
25.Lorains FK, Cowlishaw S, Thomas SA. ʻO ka hemahema o nā maʻi comorbid i ka pilikia a me ka petological gaming: ʻōnaehana hoʻolālā a me ka meta-analysis o nā haʻawina lehulehu. lama. 2011; 106: 490-498.
26.ʻO Abdollahnejad R, Delfabbro P, Denson L. Psychiatric comorbidity i ka pilikia a me ka poʻe papaʻa pathological: ke noiʻi nei i ka hopena o ka hoʻopiʻi ʻana i ka hōʻino wai. Kauka Behav. ^ E Ha yM. 2014; 39: 566-572.
27.Dowling NA, Colishaw S, Jackson AC, Merkouris SS, Francis KL, Christensen DR. ʻO ka hoʻonui ʻia o ka psychiatric co-morbidity i ka mālama ʻana i ka poʻe maʻi pilikia pilikia: kahi loiloi ʻōnaehana a me ka meta-analysis. Aust NZ J Psychiatry. 2015;49(6):519–539.
28.ʻO Hodgins DC, el-Guebaly N. ʻO ka hopena o ka hilinaʻi o ka waiwai a me nā pilikia o ka hopena ma ka hopena mai ka petological gaming: he ʻelima mau makahiki ka hahai ʻana. J Gambl Stud. 2010;26(1):117–127.
29.Kausch O. Nā hiʻohiʻona o ka hoʻohanaʻiaʻana o ka lāʻau lapaʻau ma waena o ka poʻe pili pili i nā hana pāʻani. Hōʻalo i ka hana hewa iā J. 2003; 25: 263-270.
30.Rash CJ, Weinstock J, Petry NM. Inu ʻalo ʻana i nā hiʻohiʻona o nā mea pāʻani peʻa ma mua o, ma ke ʻano, a ma hope o ka mālama ʻana i ka pāʻani. ʻO Psychol Addict Behav. 2011;25(4):664–674.
31.ʻO Cowlishaw S, Merkouris S, Chapman A, Radermacher H. Pākuʻi a me ka pilikia pilikia i ka mālama ʻana i nā mea hoʻonaninani: he loiloi ʻōnaehana a me ka loiloi meta. Hōʻalo i ka hana hewa iā J. 2014; 46: 98-105.
32.Ledgerwood DM, Downey KK. ʻO ka pilina ma waena o ka pili pilikia pilikia a me ka hoʻohana ʻana i nā mea i loko o kahi mālama mālama methadone. Kauka Behav. 2002;27(4):483–491.
33.ʻO Goldman D, ʻo Oroszi G, Ducci F. ʻO nā genetics o nā mea hoʻohui inoa: hūnā i nā genes. Nat Rev Genet. 2005;6(7):521–532.
34.Lobo DS, Kennedy JL. ʻO nā hiʻohiʻona genetic o nā pāʻani pathological: kahi pilikia paʻakikī me nā haʻalulu pili genetic. lama. 2009;104(9):1454–1465.
35.Piazza PV, Deroche-Gamonet V. He ʻōnaehana laulā o ka transistep e hoʻohui i ka hoʻohui. Psychopharmacol. 2013;229(3):387–413.
36.Koob GF, Le Moal M. Addiction a me ka ʻōnaehana antireward o ka lolo. ʻO Annu Rev Psychol. 2008; 59: 29-53.
37.Shaffer HJ, LaPlante DA, LaBrie RA, Kidman RC, Donato AN, Stanton MV. Keʻike i kahi hoʻohālikelike o kahi maʻi no ka hoʻohui ʻana: nā kīʻaha lehulehu, na etiology maʻamau. ʻO Harv Rev. Rev Psychiatry. 2004;12(6): 367–374.
38.Shah KR, Eisen SA, Xian H, Potenza MN. ʻO nā haʻawina genetic o nā petological gaming: he loiloi o ka metodoe a me ka nānā ʻana i ka ʻikepili mai ka Vietnam era twin regist. J Gambl Stud. 2005;21(2):179–203.
39.Hodgins DC, Schopflocher DP, el-Guebaly N, et al. ʻO ka hui ma waena o ka hoʻohaʻahaʻa keiki a me nā pilikia kīlepa ma kahi ʻāpana kaiāulu o nā kāne a me nā wahine. ʻO Psychol Addict Behav. 2010; 24 (3): 548.
40.Raylu N, Oei TPS. Palapala Hoʻoikaika: he loiloi loiloi. Kauka Kauka Kauka Rev. 2002;22(7):1009–1061.
41.Schreiber L, Odlaug BL, Kim SW, Hāʻawi iā JE. ʻO nā hiʻohiʻona o nā mea pāʻani pathological me kahi makua makua pilikia pilikia. Am J Addict. 2009;18(6):462–469.
42.Lee GP, Stuart EA, Ialongo NS, Martins SS. ʻO nā mākaʻikaʻi hoʻohiʻona makua a me nā pāʻani ʻoihana ma waena o kahi pūʻali koa lōʻihi o nā ʻōpio o ke kūlanakauhale. lama. 2014;109(6):977–985.
43.Wood RTA, Griffiths MD, Parke J. Impact o nā hana a me nā hiʻohiʻona hana o ka mea hana ma ke ʻano maoli. CyberPsychol Behav. 2007;10(3):354–361.
44.ʻO Verdejo-García A, Lawrence AJ, Clark L. Impulsivity ʻo ia kahi mea ilihune no ka hoʻohana ʻana i nā mea e hoʻohana ai i ka waiwai. Neurosci Biobehav. 2008;32(4):777–810.
45.Slutske WS, Eisen S, Xian H, et al. ʻO kahi noi pālua ʻelua o ka hui ma waena o ka papaʻa pathological a me nā maʻi antisocial. Ka Haawina Abnorm Psychol. 2001;110(2):297–308.
46.Kauahi DE, Gade Andavolu R, Gonzalez N, et al. ʻO ka hopena hoʻohui o nā gen neurotransmitter i nā pāʻani pathological. Kauka Genet. 2001;60(2):107–116.
47.Rodriguez-Jimenez R, Avila C, Ponce G, et al. ʻO ka polymorphism TaqIA i pili i ke kumu DRD2 e pili ana i ka haʻahaʻa haʻahaʻa a me ka liʻiliʻi o ka pale o ka pale ʻana i ka mea maʻi maʻi maʻi. Eur Psychiatry. 2006;21(1):66–69.
48.ʻO Slutske WS,ʻO Eisen S,ʻOiaʻiʻo WR, Lyons MJ, Goldberg J, Tsuang M. Nā mea likeʻole i ka pilikino pili waiwai a me ka wai inu i ka hilinaʻi i nā kāne. ʻO Arch Gen Psychiatry. 2000;57(7):666–673.
49.Beauchaine TP, Neuhaus E, Brenner SL, Gatzke-Kopp L. He mau kumu maikaʻi e noʻonoʻo ai i nā kaʻina ola e pale ai i ka noiʻi noiʻi ʻana. Dev Psychopathol. 2008;20(3):745–774.
50.Jentsch JD, Pennington ZT. ʻOi aku, ke hoʻopau ʻia: ka pale o ka pale a me kona pili i nā mea hoʻohui. Neuropharmacol. ^ E Ha yM. 2014; 76 (Māhele B): 479-486.
51.Wise RA. Role no nigrostriatal-ʻaʻole wale o mesocorticolimbic-dopamine ma ka uku a me ka hoʻohui. Nā Trends Neurosci. 2009;32(10): 517–524.
52.Zhou Y, Proudnikov D, Yuferov V, Kreek MJ. Ka lāʻau-hoʻowalewale a me ka hoʻololi ʻana i ka genetic i nā ʻōnaehana-pane-ka hopena: nā manaʻo no nā maʻi hoʻomohala kūikawā. Kaha Kū. 2010; 1314: 235-252.
53.Naqvi NH, Bechara A. ʻO ka mokupuni huna o ka addiction: ka insula. Nā Trends Neurosci. 2009;32(1):56–67.
54.Volkow ND, Baler RD. ʻ sciencelelo ʻikepili: ka wehe ʻana i ke ʻano paʻakikī. Neuropharmacol. 2014; 76: 235-249.
55.ʻO Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Hoʻohui: ma waho o ka pākuʻi uku dopamine. Manaʻo Natl Acad Sci. 2011;108(37): 15037–15042.
56.Volkow Nāna, Wang GJ, Telang F, et al. ʻO ka Cocaine cues a me ka dopamine i loko o ka dorsal striatum: keʻano o ka makemake i ka mea hōʻaiu koko. J Neurosci. 2006;26(24):6583–6588.
57.Naqvi NH, Rudrauf D, Damasio H, Bechara A. Ka pōʻino i ka insula e hōʻake i ka hoʻohanaʻana i ka ulaula. Science. 2007;315(5811): 531–334.
58.Meyer G, Schwertfeger J, Exton MS, et al. ʻO ka pane ʻana o Neuroendocrine e pili ana i ka pāʻani kasino ma ka poʻe papaʻa pilikia. Psychoneuroendocrinology. 2004;29(10):1272–1280.
59.Sinha R. Pehea ke koʻikoʻi o ka pilikia i ka hōʻemi o ka ʻona? Alkona Res. 2012;34(4):432–440.
60.Brewer JA, Potenza MN (2008). ʻO ka neurobiology a me nā genetics o ka hoʻonāukiuki luhi ka hopena: pili i nā lāʻau lapaʻau lāʻau. Biochem Pharmacol. 2008;75(1):63–75.
61.Zack M, Poulos CX. Hoʻopiʻi ka mea'onike D2 i nā hopena maikaʻi a me nā huamua o ka hopena'ai'ē ma nā pili pili pāʻani. ʻO Neuropsychopharmacology. 2007;32(8):1678–1686.
62.Volkow ND, Wang GJ, Fowler JS, et al. ʻO ka hoʻonāukiuki i nā hopena hopena o nā psychostimulants i nā kānaka e pili pū i ka hoʻonui ʻana i ka lolo dopamine a me ka noho ʻana o nā mea hoʻokae D2. J Pharmacol Exp Ther. 1999;291(1):409–415.
63.Kaʻena-Dunckley ED, Noble BN, Hentz JG, et al. Ke pāʻani nei a hoʻonui i nā makemake kuko wahine me nā lāʻau dopaminergic i ka hoʻomaha ʻole o ka wāwae syndrome. Clin Neuropharmacol. 2007;30(5):249–255.
64.Hutchison KE, Ray L, Sandman E, et al. ʻO ka hopena o ka olanzapine ma ka moʻoʻohi a me ka inu ʻawa. ʻO Neuropsychopharmacology. 2006;31(6):1310–1317.
65.ʻO Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. He kūpōpō makapō, kahibo-ho'āʻoʻia o olanzapine no ka mālamaʻana i nā pāʻani pili pāʻani poker. Pharmacol Biochem Behav. 2008;89(3):298–303.
66.McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE. ʻOlanzapine i ka mālamaʻana i ka palaka pathological: kahi hoʻokolokolo hoʻokūkū hoʻokūkū hoʻokūkū maikaʻi ʻole. Ka Haumānaʻo J Clin. 2008;69(3):433–440.
67.Krueger TH, ʻo schedlowski M, Meyer G. Cortisol a me nā koina o ka puʻuwai ma ke alo o ka pāʻani casino ma ka pili ʻana i ka impulsivity. Neuropsychobiology. 2005;52(4):206–211.
68.Potenza MN, Leung HC, Blumberg HP, et al. ʻO kahi hana hana hana FMRI Stroop no ka hana cortical ventromedial prefrontal cortical ma nā papaʻaʻomaʻo pathological. Ka Ike Kahuna. 2003;160(11):1990–1994.
69.Leeman RF, Potenza MN. Nā mea like a me nā ʻokoʻa ma waena o ka petological gaming a me nā mea hoʻohana e hoʻohana ai i nā maʻi: he mau manaʻo o ka impulsivity a me ka compulsivity. Psychopharmacol. 2012;219(2):469–490.
70.Stavro K, Pelletier J, Potvin S. Hoʻonui loa a mālama ʻia i nā hemahema cognitive i loko o ka ʻawaʻawa: a meta-analysis. Hoʻohui Biol. 2013;18(2):203–213.
71.Ledgerwood DM, Alessi SM, Phoenix N, Petry NM. ʻO ka loiloi whanui. Waiʻi ka waiʻona waiʻona. 2009;105(1):89–96.
72.Brand M, Kalbe E, Labudda K, Fujiwara E, Kessler J, Markowitsch HJ. Nā hoʻoholo hoʻoholo. ʻO ka hauā hau. 2005;133(1):91–99.
73.Fuentes D, Tavares H, Artes R, Gorenstein C. Hoike i hōʻike ʻia a me nā hana neʻe ʻana o ka neuropsychological i ka hoʻopunipuni i ka pāʻani papa. J IntNeuropsychol Soc. 2006;12(06):907–912.
74.Vitaro F, Arseneault L, Tremblay RE. Kuhi ʻo Impulsivity i ka pāʻani pili ʻana i ka hana pili i nā kāne ʻōpio haʻahaʻa SES. lama. 1999;94(4): 565–575.
75.ʻO Lawrence AJ, Luty J, Bogdan NA, Sahakian BJ, Clark L. ʻO nā mea mālama pilikia ke kaʻana aku i nā hemahema i ka hoʻoholo ʻana i ka hoʻoholo a me nā mea inu ʻona. lama. 2009;104(6):1006–1015.
76.Slutske WS, Caspi A, Moffitt TE, Poulton R. ʻO ka pilikino a me ka pilikia ke pilikia: he hoʻopaʻa noiʻi ʻana o kahi cohort hānau hānau o ka ʻōpio makua. ʻO Arch Gen Psychiatry. 2005;62(7):769–775.
77.ʻO Goudriaan AE, ʻo Oosterlaan J, de Beurs E, ʻo Van den Brink W. Pāʻani papa: ʻo ka loiloi piha ʻana o ka ʻike biobehālie. ʻO Neurosci Biobehav Rev. 2004;28(2):123–141.
78.Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ. Hoʻomake ka hoʻoilo ʻana mai ka wai inu wai DSM-IV: United States, 2001-2002. lama. 2005;100(3):281–292.
79.ʻO Wuts Slutske. ʻO ka hōʻailona kūlohelohe a me ka huliʻana i nā mea e pono ai i loko o ka pāʻani pāʻani: nā hopena oʻelua mau noiʻi'āina o US. Ka Ike Kahuna. 2006;163(2):297–302.
80.Rash CJ, Petry NM. Nā mālama naʻau no ka maʻi ʻaʻa laka. ʻĀina Pule Psychol Res Behav. 2014; 7: 285-295.
81.Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. ʻO kahi loiloi meta-analytic no nā pale naʻau psychosocial no nā pilikia hoʻohana. Ka Ike Kahuna. 2008;165(2):179–187.
82.ʻO Kelly JF, Stout RL, Zywiak W, Schneider R. A 3 aʻoʻelima makahiki i ka hoʻohui ʻana i ka hui like ʻana i nā hui kōkua ma hope o ka hana maʻi outpatient ikaika loa. Ka Waiʻona Clin Exp Res. 2006;30(8):1381–1392.
83.Moos RH, Moos BS. Ke komo nei i ka mālama ʻana a me ke Alcoholics Anonymous: kahi hana ʻana he 16 makahiki a mua o ka poʻe i loaʻa ʻole ʻia. J Kaukaʻi Kauka. 2006;62(6):735–750.
84.Moos RH, Moos BS. Nā ala e komo ai i nā mea inu wai ʻole: nā hopena no ke komo ʻana a me ke kala ʻana. Ka Waiʻona Clin Exp Res. 2005;29(10):1858–1868.
85.Petry NM. ʻO nā hōʻailona a me nā mea hoʻoliʻelima o nā poʻe Gamblers ʻO kahi hiki ʻole i ke kau inoa ma nā mea pāʻani gambological e ʻimi nei i ka mālamaʻike. Kauka Behav. 2003;28(6):1049–1062.
86.Hāʻawi iā JE, Donahue CB, Odlaug BL, Kim SW, Miller MJ, Petry NM. Hoʻolauleʻa manaʻo ʻokoʻa a me ke ʻano hoʻoikaika o ka ninaninau pili i ka petological gaming: ua hoʻokolokolo ʻia ka randomized trial. Br J Hoʻonaʻauao. 2009;195(3):266–267.
87.Stewart RM, Palapala RI. He hopena hopena o Gamblers Anonymous. Br J Hoʻonaʻauao. 1988;152(2):284–288.
88.Petry NM, Ammerman Y, Bohl J, et al. Cognitive-hanana e pili ana i ka hoʻomaʻamaʻa pathological. J Consult Clin Psychol. 2006;74(3):555–556.
89.ʻO Petry NM. Pili Kani: Kaupio, Kākoʻo, a me nā Kuʻuna. ^ E Ha yM. Wakinekona, DC: ʻAmelika Kūlana ʻAmelika; 2005.
90.ʻO Gainsbury S, Blaszczynski A. ʻO ia iho ke alakaʻi pilikino pūnaewele no ka mālama ʻana i ka pāʻani pili pilikia. Int Gambl Stud. 2011; 11: 289-308.
91.Apodaca TR, Miller WR. ʻO kahi meta-ka nānā ʻana o ka hopena o ka bibliotherapy no nā pilikia waiʻona. J Kaukaʻi Kauka. 2003;59(3): 289–304.
92.LaBrie RA, Peller AJ, LaPlante DA, et al. Kahi pono kōkua kōkua pilikino ponoʻī no ka pilikia ʻoihana pāʻani: he hoʻokolokolo multisite randomized. Am J Orthopsychiatry. 2012;82(2):278–289.
93.ʻO Hodgins DC, Currie SR, el-Guebaly N. Hoʻonui ʻana i ka hoʻoikaika ʻana a me ka mālama ʻana i ke kōkua ponoʻī no ka palaka pilikia. J Consult Clin Psychol. 2001;69(1):50–57.
94.ʻO Hodgins DC, Currie S, el-Guebaly N, Peden N. ʻO kahi hoʻomaʻamaʻa pōkole e pili ana i ka hoʻāʻo ʻana no ka pilikia pilikia: he mākaʻi me kahi mahina 24. ʻO Pyschol Addict Behav. 2004;18(3):293–296.
95.Smedslund G, Berg RC, Hammerstrøm KT, et al. Nīnauele kumu no ka hōʻino ʻana i ka waiwai. Cochrane Database System Rev. ^ E Ha yM. 2011; (5): CD008063.
96.Diskin KM, Hodgins DC. ʻO kahi hoʻokolohua kākelepule hoʻopaʻa ʻia ʻana o ka papa hālāwai hoʻoliʻeu me ka papaʻa mau mea pili i nā mea pāʻani. Behav Res Ther. 2009;47(5):382–388.
97.Cunningham JA, Hodgins DC, Toneatto T, Rai A, ʻO Cordingley J. Pilot ka noiʻi ʻana mai i kahi kikowaena pane pilikino ponoʻī no ka poʻe ʻōpio pilikia. Behav Ther. 2009;40(3):219–224.
98.Petry NM, Weinstock J, Ledgerwood DM, Morasco B. ʻO kahi hoʻokolohua kapu ʻole o nā wawaʻi pōkole no nā pilikia a me nā mea pāʻani pathological. J Consult Clin Pscyhol. 2008;76(2):318–328.
99.Petry NM, Weinstock J, Morasco BJ, Ledgerwood DM. Hoʻopuka pōkole pōkole no nā mea pāʻani haumāna pilikia haumāna kolepa. lama. 2009;104(9):1569–1578.
100.Larimer ME, Nā Mokupuni C, Lostutter TW, et al. ʻO ka ʻōlelo hoʻonaninani puʻupuʻu a me nā mea hoʻowalewale cognitive hoʻohaʻahaʻa no ka pale ʻana i ka moʻo pāʻani i kuhihewa ʻia: ka hoʻokolohua hoʻokūkū paʻa. lama. 2011;107(6):1148–1158.
101.ʻO Carlbring P, ʻo Jonsson J, Josephson H, ʻo Forsberg L. Motivational ke kūkākūkā me ka hui ʻana o nā pūʻulu kumuhana kognitive ma ka mālama ʻana i ka pilikia a me ka petological gaming: he hoʻokolohua hoʻokele randomized. Cogn Behav Ther. 2010;39(2):92–103.
102.Dowling N, Smith D, Thomas T. He hoʻohālikelike o ka hōʻuluʻulu ʻana o ka manaʻo a me ka hui ʻana o ka mālama ʻana i ka ʻaʻano wahine no ka pili ʻana i ka wahine. Behav Res Ther. 2007;45(9):2192–2202.
103.Jimenez-Murcia S, Aymami N, Gomez-Peña M, et al. Hoʻonui ka ʻike a me ka pane ʻana i ka hopena o ka hui cognitive-behavior therapy no ka male slot machine pathological gamblers? Kaukaʻi Kauka J J. 2012;51(1):54–71.
104.ʻO ka hui noiʻi papahana noiʻi. Ke hoʻomau nei i nā mālama ʻalekane i ka heterogeneity kanaka: Hoʻopau i nā hua inu inu posttreatment Project MATCH. J Stud Alakana. 1997; 58: 7-29.
105.Ladouceur R, Sylvain C, Boutin C, et al. Cognitive lapaʻau o ka pāʻani pathological. J Nerv Ment Dis. 2001;189(11):774–780.
106.ʻO Ladouceur R, Sylvain C, Boutin C, Lachance S, Douet C, Leblond J. Group therapy no nā poʻe pāʻani papa keʻa: he hana kuli. Behav Res Ther. 2003;41(5):587–596.
107.Toneatto T, Gunaratne M. Ua hoʻomaikaʻi anei ka mālamaʻana o nā kolohe kognitive i nā hopena kulekele no ka pili pilikia? J Contemp Pikaila. 2009; 39: 221-229.
108.Jiminez-Murcia S, Granero R, Fernandez-Aranda F, et al. ʻO nā wanana i waena o ka hopena i waena o nā mea pāʻani gambological e loaʻa ana i ka hui ʻana o ka hui mālama kognitive. He ʻaina Euro Lūkini. 2015; 21: 169-178.
109.Moghaddam JF, Campos MD, Myo C, Reid RC, Fong TW. ʻO ka nānā lōʻihi lōʻihi o ke kaumaha i waena o ka poʻe maʻi hānai. J Gambl Stud. 2015;31(4):1245–1255.
110.ʻO Petry NM, ʻo Blanco C. Nā loiloi pili aupuni ma United States: e haʻi hou ka moʻolelo iā ia iho? lama. 2012;108(6):1032–1037.
111.Blanco C, Hanania J, Petry NM, et al. Ke hele nei i kahi hoʻolālā hoʻomohala holoʻokoʻa o ka pāʻani pathological. lama. 2015;110(8): 1340–1351.
112.Leavens E, Marotta J, Weinstock J. Kaʻaila hoʻoweliweli ma nā hale noho e hoʻohana ai i nā kikowaena mālama mālama: pono ʻole. J Addict Dis. 2014;33(2):163–173.